SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?


To: Jim Oravetz who wrote (329)6/6/2002 10:38:06 PM
From: mopgcw  Read Replies (1) | Respond to of 523
 
3:15PM Neurogen falls on talk of Pfizer cancellation (NRGN) 8.52 -1.79: Stock slumped in early trading and has been bouncing near its low since; we are hearing that the stock sold off because their partner PFE has pulled out of an agreement; while NRGN has disclosed numerous royalty-paying technology transfers and research collaborations with PFE, we have no details as to which deal was rumored to be cancelled.